/ Alembic Pharma Receives USFDA Approval For Fenofibric Acid Delayed-Release Capsules ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 15 May 2017

Alembic Pharmaceuticals Limited on Monday, 15 May 2017, in a BSE filing announced that the company has received approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Fenofibric Acid Delayed-Release Capsules 45 mg and 135mg.

Fenofibric Acid Delayed-Release Capsules have an estimated market size of USD 93 million for twelve months ending December 2016 according to IMS, said Alembic Pharma.

Alembic now has a total of 56 ANDA approvals (50 final approvals and 6 tentative approvals) from USFDA, it also added. The stock of Alembic Pharmaceuticals Limited is trading up by over 1% in the early morning trade on the BSE on Monday, 15 May 2017.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717